Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study (NCT05673148)
A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients With Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)
🩺 Plain-English Summary (8th-Grade Level)
This phase III trial compares total ablative therapy and usual systemic therapy to usual systemic therapy alone in treating patients with colorectal cancer that has spread to up to 4 body sites (limited metastatic). The usual approach for patients who are not participating in a study is treatment with intravenous (IV) (through a vein) and/or oral medications (systemic therapy) to help stop the cancer sites from getting larger and the spread of the cancer to additional body sites. Ablative means that the intention of the local treatment is to eliminate the cancer at that metastatic site. The ablative local therapy will consist of very focused, intensive radiotherapy called stereotactic ablative radiotherapy (SABR) with or without surgical resection and/or microwave ablation, which is a procedure where a needle is temporarily inserted in the tumor and heat is used to destroy the cancer cells. SABR, surgical resection, and microwave ablation have been tested for safety, but it is not scientifically proven that the addition of these treatments are beneficial for your stage of cancer. The addition of ablative local therapy to all known metastatic sites to the usual approach of systemic therapy could shrink or remove the tumor(s) or prevent the tumor(s) from returning.
Who can join: Review the eligibility criteria below.
Location: Kingman Regional Medical Center — Kingman, Arizona
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (187 Sites)
Showing the first 25 of 187 sites.
- Kingman Regional Medical Center — Kingman, Arizona
- Mayo Clinic Hospital in Arizona — Phoenix, Arizona
- Tower Cancer Research Foundation — Beverly Hills, California
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care — Irvine, California
- Cedars-Sinai Medical Center — Los Angeles, California
- UC Irvine Health/Chao Family Comprehensive Cancer Center — Orange, California
- University of California Davis Comprehensive Cancer Center — Sacramento, California
- Beebe Medical Center — Lewes, Delaware
- Beebe South Coastal Health Campus — Millville, Delaware
- Helen F Graham Cancer Center — Newark, Delaware
- Medical Oncology Hematology Consultants PA — Newark, Delaware
- Christiana Care Health System-Christiana Hospital — Newark, Delaware
- Beebe Health Campus — Rehoboth Beach, Delaware
- Christiana Care Health System-Wilmington Hospital — Wilmington, Delaware
- Sibley Memorial Hospital — Washington D.C., District of Columbia
- George Washington University Medical Center — Washington D.C., District of Columbia
- UM Sylvester Comprehensive Cancer Center at Coral Gables — Coral Gables, Florida
- UM Sylvester Comprehensive Cancer Center at Coral Springs — Coral Springs, Florida
- UM Sylvester Comprehensive Cancer Center at Deerfield Beach — Deerfield Beach, Florida
- UM Sylvester Comprehensive Cancer Center at Doral — Doral, Florida
- UF Health Cancer Institute - Gainesville — Gainesville, Florida
- UM Sylvester Comprehensive Cancer Center at Hollywood — Hollywood, Florida
- Jupiter Medical Center — Jupiter, Florida
- University of Miami Miller School of Medicine-Sylvester Cancer Center — Miami, Florida
- Miami Cancer Institute — Miami, Florida
📞 Contact the Study Coordinator
Phone: (614) 685-4922
Email: eric.miller@osumc.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Metastatic Colorectal Adenocarcinoma
- Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders — Houston, Texas
- Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study — Kingman, Arizona
- Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer — Gainesville, Florida
- Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer — Bay City, Michigan
- Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal Cancer — Fullerton, California
Explore by condition: All Metastatic Colorectal Adenocarcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.